Our thanks go to the following readers for thefollowing reasons.
First, to Glenn Lammi over at the Washington Legal Foundation, who inresponse to our Caronia Roundup, pointed out that WLF was having a Web Seminaron the subject. Unfortunately, it was today. Too bad we didn’t getaround to posting this in time for the seminar. We'll try to be better next time.
Then there’s Calvert Crary, who sent us a PDFof his Caronia analysis (which wemissed - even knowing about it we'll be damned if we can find it on the Web anywhere), which is interesting because it breaks down possible effectsof the decision by large branded, small branded, and generic companies. This is the only analysis that we’ve seen that analyzes things this way.
Finally, thanks to Dr. John Duke (yes, some M.D.sactually read the blog) an assistant professor at Indiana University MedicalSchool whoinforms us of his studydiscovering that there were more discrepancies between generic and branded labeling than wethought, although most of them were quite minor. A word to the wise – this time our readersin the generic business – since generic preemption is based on “sameness”between generic and branded labeling, it would be a good idea not to risk your best defense but not having labels that actually are thesame.
Hiç yorum yok:
Yorum Gönder